Harpoon Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update Dosed first patient with HPN217 for the treatment of multiple myeloma, triggering a $50 million milestone payment from AbbVieAbstract for HPN424 interim Phase 1 data accepted for presentation at...

Harpoon Therapeutics Doses First Patient with HPN217, a BCMA Targeting TriTAC, for Multiple Myeloma SOUTH SAN FRANCISCO, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...

Harpoon Therapeutics Appoints Two New Members to Its Board of Directors Andrew R. Robbins, former Chief Operating Officer, Array BiopharmaDr. Joseph S. Bailes, former President of American Society of Clinical Oncology (ASCO) SOUTH SAN FRANCISCO, Calif., April 01, 2020 ...

Harpoon Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Corporate Update Exclusive worldwide option and license transaction for HPN217 with AbbVie and expansion of existing discovery collaboration in November 2019 could provide up to $100 million in upfront/near-term...

Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon’s BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration Harpoon grants AbbVie option to license worldwide rights to HPN217 (BCMA), a TriTAC for the treatment of multiple myeloma planned for IND filing this year Expanded TriTAC discovery collaboration...